McKesson Corporation vs Newegg Commerce Inc — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Newegg Commerce Inc trades at $11.58 (market cap $243.30M). The key difference: McKesson Corporation is far larger — about 445.8× Newegg Commerce Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Newegg Commerce Inc for 14 Days on average.
| MCK | NEGG | |
|---|---|---|
Market Cap | $108.46B | $243.30M |
Volume | 712,607 | 41,252 |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $92.74 |
52-Week Low | $725.17 | $11.49 |
Typical Hold Time | 74 Days | 14 Days |
Enterprise Value | $115.00B | $213.53M |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
NEGG trades at $11.58, down 3.58% on the day, with a bearish technical signal from moving averages but oversold RSI readings. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.11 versus a -$0.40 estimate. The company shows improving fundamentals, with revenue stabilizing around $1.4B and net losses narrowing significantly in 2025. New partnerships with Western Digital and Hewlett Packard Enterprise highlight strategic moves in IT infrastructure.
The outlook is mixed; improving profitability and low P/S ratio offer value, but negative operating cash flow and insider selling pose risks. Analyst consensus is a Buy with a $7.75 target, below the current price, indicating caution. Key risks include competitive pressures and reliance on financing activities for liquidity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →